

The phase angle is associated with upper arm muscle circumference but not with sarcopenia in
continuous ambulatory peritoneal dialysis patients

Ye Chen, Jinlan Wu, Lei Ran, Dan Yu, Xi Chen, Maodong Liu*

Ye Chen: graduate student of The third hospital of Hebei medical university, nephropathy, E-

mail:chenye18821756225@163.com

Jinlan Wu: graduate student of The third hospital of Hebei medical university, nephropathy, E-

mail:2101414705@qq.com

Lei Ran: The senior nurse of the third hospital of Hebei medical university, nephrology department,

bachelor's, E-mail:1970489020@qq.com

Dan Yu: The hematologist of the third hospital of Hebei medical university, nutritional department,

PhD, E-mail:yudan20122013@163.com

Xi Chen: graduate student of The third hospital of Hebei medical university, nephropathy, E-mail:

cx1270274621@163.com

Maodong Liu: The professor of the third hospital of Hebei medical university, nephrology department

*Corresponding author: Maodong Liu, E-mail:lmdgxh@123.com, Man, Han Chinese, Xingtai City,

Hebei Province, China, PhD

Word counts for the abstract: 245 words

Word counts for the body of the manuscript: 2936 words

Authors' contributions YC collected body composition analysis data from patients, performed

statistical analysis of the data, and wrote the first draft; JL, W was in charge of screening the

patients; MD, L, and DY were responsible for the experimental design and revision the paper; LR

was responsible for collecting data on patients' grip strength and follow up the patients; XC

collated and checked all the data.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Aims: Limited studies on phase angle (PhA) and sarcopenia in continuous ambulatory peritoneal dialysis (CAPD) patients. We want to explore the association between PhA and sarcopenia and clarify its significance and value in diagnosing sarcopenia.

Methods: We included 87 CAPD patients. We measured the PhA and body composition by bioelectrical impedance analysis. All patients had their handgrip strength (HGS) measured. Then, we divided patients into the sarcopenia (n=25) group and non-sarcopenia(n=62) group according to the sarcopenia diagnostic strategy formulated by the Asian Working Group for Sarcopenia.

Results: Univariate analysis shows PhA is positively associated with HGS, skeletal muscle mass (SMM), and Upper arm muscle circumference (AMC). After adjustments for sex, age, diabetes, BMI, extracellular water ratio(E/T), extra water (OH), serum creatinine, total kt/v, and residual kt/v, PhA remains correlated to HGS and AMC, but

not to SMM. In the multivariate logistic model, PhA is not correlated to sarcopenia.

The AUROC of PhA for sarcopenia is 0.76(95% CI, 0.65-0.86, $P < 0.01$, fig 3). The optimal cut-off value is identified as ≤ 5.25 (sensitivity 74%, specificity 76%).

Conclusion: This study illustrates that older age and higher total kt/v are risk factors for sarcopenia. PhA is positively associated with HGS and AMC but not with sarcopenia in CAPD patients. These results suggest that PhA can predict muscle mass and strength in CAPD patients, but its diagnosis value for sarcopenia needs more studies.

Keywords: continuous ambulatory peritoneal dialysis(CAPD), the body composition analysis, upper arm muscle circumference, phase angle

Introduction

Sarcopenia is the loss of muscle mass, strength, or muscle function, which was initially thought to be an age-related disease[1]. In contrast, recent studies showed that some inflammatory diseases, such as tumors and organ failure, could increase the risk of sarcopenia[2]. In addition, sarcopenia is one of the most important complications in patients undergoing peritoneal dialysis due to micro-inflammatory state, inadequate caloric intake, uremic toxin accumulation, volume overload, and peritoneal dialysis process [3], with a prevalence of 4%-15.5%[4, 5]. Several studies demonstrated that sarcopenia was associated with physical disabilities, higher mortality, cardiovascular events, and falls in chronic kidney disease (CKD). In 2015, a prospective analysis of hemodialysis (HD) patients presented a higher risk of disabilities in sarcopenia than non-sarcopenia group[6]. Yuka et al.[7]enrolled 119 PD patients and found that sarcopenia was associated with a higher risk of mortality (survival mortality rate per

500 days: 0.667 in the sarcopenia group vs. 0.971 in the non-sarcopenia group, $p < 0.001$). Then, a study of elderly HD patients showed sarcopenia patients presented a higher risk of falls than non-sarcopenia ones. According to a prospective observation study[8], sarcopenia was a strong predictor of death (HR, 6.99; 95% CI, 1.84 to 26.58; $p = 0.004$) and cardiovascular events (HR, 4.33; 95% CI, 1.51 to 12.43; $p = 0.006$). In addition to this, a multicenter analysis confirmed a correlation between sarcopenia and a high risk of hospitalization in HD patients (RR, 2.07, 95% CI, 1.48-2.88, $P < 0.001$). In summary, the use of easily accessible and cheaper instruments to test the nutritional status of patients is extremely important for the diagnosis and early prevention of sarcopenia in clinical practice.

Bioelectrical impedance analysis (BIA) is quick and relatively noninvasive to analyze the body composition of the human body, which can measure muscle, fat, and water separately[9]. Thus, it has been widely used for body composition measurement. BIA is more valuable in chronic kidney disease due to the volume overload in those patients. Recent guidelines recommend BIA could be used to estimate muscle mass in diagnosing sarcopenia[2]. PhA was an indicator measured by BIA and has been gaining attention because it reflected the cellular function and the distribution of intracellular and extracellular water[10]. Several studies found it correlated to muscle strength and function[11, 12]. Thus, the current evidence encouraged research on the use of PhA in the nutrition care process and diagnosis, particularly in sarcopenia. Many studies have explored the relationship between sarcopenia and PhA in different diseases, including patients undergoing PD.

However, there are few studies on Chinese CAPD patients. After all, the phase angle value varies from one race to another[13].

In clinical practice, there are many CAPD patients in our nephrology clinic. Exploring easy ways to find sarcopenia in these patients draws our attention. This study wants to explore the association between PhA and sarcopenia in Chinese CAPD patients. Meanwhile, we want to find an optimal cut-off value of sarcopenia diagnostic in these patients.

Materials and methods

Study design and patient recruitment

This cross-sectional study was carried out between August 2021 and March 2022. It evaluated CAPD patients in the Peritoneal Dialysis Clinic of The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei Province. Inclusion criteria were patients aged >18 years, on stable dialysis>3 months, and with regular follow-up. Patients with acute infection at any site (respiratory, digestive, urinary), acute cardiovascular disease, malignancy, active liver disease, tuberculosis, AIDS, syphilis, and other systemic diseases, surgery, trauma, or disability resulting in deficient grip strength and body composition analysis data were excluded. The Ethics Committee approved the study protocol of The Third Hospital of Hebei Medical University (**number:20210931**). All subjects signed an informed consent form.

Anthropometric measurements

The Clinical nutrition test analyzer (AINST 2018, Taizhou city, Jiangsu province, China) records the patient's body weight with a precision of 1g (we will

subtract the weight of peritoneal fluid when measuring). Height was measured by a Portable height measuring instrument with a precision of 0.1cm.

Body composition analysis and phase angle

Determination of body composition, PhA and AMC use a clinical nutrition test analyzer based on the BIA method. Subjects were asked to fast for at least 8 hours and empty their urine and stool in the early morning of the test. Measurement method: Clean the electrode contact surface of the instrument with an alcohol cotton ball, measure the height and weight of the subject; the subject is barefoot, wipe the soles of both feet and palms of both hands with an alcohol cotton ball, make both feet and hands contact the silver electrode contact surface of the instrument to the maximum extent, and introduce the current. Start to measure and read total water, extra water (OH), protein, skeletal muscle mass (SMM), body fat, appendicular skeletal muscle mass index (ASMI), extracellular water ratio(E/T), AMC, PhA, and other data.

Baseline variables

Sociodemographic backgrounds were obtained via face-to-face interviews, including name, sex, and age. Clinical data, including dialysis vintage, blood pressure, and year diagnosed with ESRD, come from electronic or paper cases from our center. Routine laboratory tests, including high-sensitive C-reactive protein(Hs-CRP), serum hemoglobin, and so on, were collected from medical records. Blood samples are collected on an empty stomach on the morning of the day of the body composition measurement.

Grip strength

Handgrip strength (HGS) is measured by a Grip Strength meter (CAMRY, MODEL: EH101). We ask subjects to turn their palms inward with the dial facing outward. Their bodies stand upright, and their arms hang down naturally. The grip meter should not contact their bodies and clothes. Then, use the force of the muscle group of the main hand to measure three times and take the average value.

Total Kt/V_{urea} Assessment

A 24 h urine sample and dialysis fluid specimen were collected, and fasting venous blood was taken in the morning of the following day. Kt/V_{urea} is calculated. At the same time, professionals checked and recorded Dialysis protocol, urine volume, and ultrafiltration volume for the day.

$$\text{Total } Kt/V = \text{Dialysis } Kt/V + \text{Residual renal } Kt/V$$

$$\text{Dialysis } Kt/V = \text{dialysate urea (mmol/L) / serum urea (mmol/L)} \times 24 \text{ h abdominal dialysate excretion volume (L)} \times 7 / \text{body weight (kg)} \times 0.60(\text{male}) / 0.55(\text{female})$$

$$\text{Residual renal } Kt/V = 24 \text{ h urine urea (mmol/L) / serum urea (mmol/L)} \times 24 \text{ h abdominal dialysis fluid excretion Volume (L)} \times 7 / \text{body weight (kg)} \times 0.60 (\text{male}) / 0.55 (\text{female})$$

Sarcopenia Diagnosis

According to the Asian sarcopenia diagnostic strategy formulated by the Asian Working Group for Sarcopenia (AWGS), the subjects should meet the following two criteria of the BIA test: 1. appendicular skeletal muscle mass index

$$(\text{ASMI}) = \text{appendicular skeletal muscle (kg)} / \text{height (m}^2\text{)}: \text{Males} < 7.0 \text{ kg/m}^2,$$

Females < 5.7 kg/m²; 2. Handgrip strength: Males < 26 kg, females < 18 kg.

Statistical Analysis

We analyzed the data using the statistical software IBM SPSS Statistics version 26.0 (SPSS Inc., Chicago, IL, United States). Continuous variables with normal distribution were presented as mean \pm standard deviation (SD), whereas skewed data were presented as median (q1–q3). The number of cases (percentage) was used for categorical counts.

The Pearson product-moment correlation assesses the correlation between PhA and diagnostic indicators of sarcopenia. Logistic regression analysis is performed to assess the independent predictors of sarcopenia. A multivariate analysis is adjusted for age, total Kt/V, residual kidney Kt/V, basal metabolic, OH, E/T and serum creatinine.

We use a receiver-operating characteristics (ROC) curve analysis to determine diagnostic accuracy and the cut-off point for PhA to detect sarcopenia. The area under the curve (AUC) indicates the discriminative power of the test. The Youden index calculated the best cut-off value in the AUC. $P < 0.05$ was considered a statistically significant difference.

Results

1. The basic information of peritoneal dialysis patients.

A total of 102 patients on peritoneal dialysis came to our outpatient clinical from September 2021 to March 2022. Seven patients had been on peritoneal dialysis for less than three months. Four patients refused to be enrolled, two patients had hemiplegia of the limbs due to old cerebral infarction, and two were younger than 18 years old. Eighty-seven patients were finally enrolled, including 43 males (49.43%)

and 44 females(50.57%), with a mean age of 51.3±12.43 years, and 25 patients were diagnosed with sarcopenia. (Table 1)

2. The comparison between the sarcopenia group and non-sarcopenia group.

Age is significantly higher in the sarcopenia group than in the non-sarcopenia group. The total Kt/V and residual kidney Kt/V are higher in the sarcopenia group than in the non-sarcopenia group. But the total Kt/v in non-sarcopenia patients is approximately 1.7, which is the best total Kt/v for peritoneal dialysis patients. The body composition analysis shows that basal metabolic rate, PhA, cell mass, de-fatted body weight, protein, skeletal muscle, muscle mass, intracellular water, serum calcium, serum sodium, serum albumin, serum pre-albumin, serum creatinine, and parathyroid hormone (PTH) are all lower in the sarcopenia group than the non-sarcopenia group;. In contrast, excess water and E/T are higher in the sarcopenia group than in the non-sarcopenia group. (Table 1)

Table 1 Comparison of general condition, grip strength, body composition analysis and hematological indices in sarcopenic and non-sarcopenic abdominal dialysis patients

Variables	Total	Sarcopenia group	Non-sarcopenia group	t/z/ χ^2 value	P-value
Baseline variables					
Age	51.3±12.43	62.12±9.20	46.94±10.83	6.169	<0.01
Sex	Male 43 (49.43%)	Male 10 (40%)	Male 33(53.23%)	1.247 ^a	0.264
DM	Yes 17 (19.54%)	Yes 7	Yes 10	1.597 ^a	0.2
SBP	141.03±11.59	141(130-150)	141.5(132.75-150)	-0.028	0.98
DBP	90(87-99)	90(86-96.5)	90(87.75-99)	-0.557	0.58
Dialysis age (month)	34(17-71)	21(16-72)	37.5(17.75-70.25)	-0.685	0.493
Bioelectrical impedance analysis					
BFP (%)	26.64±9.54	29.31±11.14	25.56±8.68	1.676	0.097
WHR	0.82±0.10	0.83±0.11	0.82±0.09	0.339	0.74
AC (cm)	28.93±3.37	28.11±3.21	29.26±3.40	-1.449	0.151
AMC (cm)	23.44±2.48	22.69±2.16	23.75±2.55	-1.830	0.071
BMI (kg/m ²)	23.9(20.8-26.6)	24.4(20.95-25.85)	23.6(20.73-26.73)	-1.88	0.85
BMR (kcal)	1368.61(1206.85-1598.16)	1279.16(1198.48-1394.91)	1445.35(1203.25-1617.87)	-1.988	0.047
PhA (°)	5.4(4.5-5.8)	4.5(4.05-5.3)	5.45(5.2-5.9)	-3.786	<0.018

Cell mass(kg)	28.91(24.36-35.62)	27.23(23.83-29.99)	31.65(24.46-37.08)	-2.22	0.027
LBM (kg)	46.23(38.74-56.86)	42.09(38.355-47.45)	49.79(38.58-57.77)	-1.988	0.047
VFA (cm ²)	72.89(60.13-106.73)	96.59(62.71-138.84)	72.09(53.87-101.53)	-1.505	0.132
BMC (kg)	2.73(2.34-3.19)	2.66(2.36-2.84)	2.92(2.32-3.33)	-1.674	0.094
Protein (kg)	8.73(7.35-10.75)	8.22(7.19-9.06)	9.55(7.38-11.19)	-2.214	0.027
SMM (kg)	24.32(20.18-30.43)	22.79(19.70-25.31)	26.82(20.27-31.77)	-2.223	0.026
Muscle mass(kg)	43.45(36.11-53.48)	39.64(35.86-44.61)	46.93(36.20-54.54)	-2.026	0.043
ECW (L)	13.59(11.33-16.81)	12.43(11.45-14.47)	14.63(11.11-17.11)	-1.459	0.145
ICW (L)	20.18(17.01-24.87)	19.01(16.64-20.94)	22.10(17.08-25.89)	-2.214	0.027
Total water(L)	34.05(28.34-42.07)	30.92(28.22-34.99)	36.86(28.28-42.73)	-1.928	0.054
OH(L)	1.21(0.75-1.9)	1.4(1.21-1.95)	1.10(0.70-1.88)	-2.303	0.021
E/T	0.4(0.39-0.41)	0.4(0.4-0.42)	0.39(0.39-0.4)	-3.7	<0.01
Routine laboratory tests					
Dialysis dose(ML)	8552(6280-9090)	8420(6145-8930)	8617.5(6318.25-9100)	-1.013	0.311
Total Kt/V	1.80±0.29	1.93±0.35	1.74±0.25	2.791	<0.01
Residual kidney kt/V	0(0-0.473)	0.236(0-0.80)	0(0-0.30)	-2.528	0.011
Dialysis kt/V	1.54(1.34-1.80)	1.601(1.27-1.84)	1.53(1.35-1.80)	-0.01	0.996
Hb	110(103-120)	110(103-118.5)	109.5(102.75-122)	-0.028	0.978
Hs-CRP	3.52(1.78-9.87)	3.2(1.58-6.97)	3.6(1.93-11.27)	-1.018	0.309
ALB	38.61(35.82-41.47)	36.66(33.83-39.08)	39.09(36.05-42.63)	-2.762	0.006*
TIBC	44.05(36.96-50.5)	43.2(35.68-47.84)	44.63(37.34-52.82)	-1.116	0.264
FER	194.44(77.03-407.69)	153.62(80.20-367.28)	197.99(75.47-425.19)	-0.347	0.729
SI	11.26(9.29-14.5)	11.61(8.66, 13.81)	11.12(9.52-15.34)	-0.657	0.511
TS	0.26(0.21-0.34)	0.28(0.23, 0.33)	0.25(0.20-0.34)	-0.919	0.358
Cr	984.06(812.54-1187.94)	806.37(621.86-959.23)	1074.07(897.06-1287.97)	-4.596	<0.01
BUN	19.88(16.55-23.05)	19.91±4.92	20.76±4.81	-0.736	0.464
HCO ₃ ⁻	25.00±2.71	24.43±2.49	25.23±2.78	-1.252	0.214
PA	369.7(323.2-414.4)	326.9(289.65-383.7)	379.25(339.25-424.83)	-2.598	<0.01
TG	1.45(1.13-2.32)	1.32(1.01-2.09)	1.55(1.15-2.33)	-1.177	0.239
TC	5.15±1.13	5.22±1.07	5.11±1.16	0.387	0.7
HDL	1.26(1.01-1.54)	1.35(1.04-1.76)	1.22(1.01-1.47)	-1.229	0.219
LDL	2.85±0.74	2.85±0.65	2.86±0.78	-0.031	0.975
VLDL	0.68(0.51-1.19)	0.63(0.5-2)	0.7(0.51-1.05)	-0.403	0.687
ALP	75(59-107)	76(61-102.5)	74(58-108.5)	-0.277	0.782
PTH	212.2(468.3-727.4)	338.5(192.75-541.2)	538.55(212.5-770.28)	-1.984	0.047

DM: Diabetic Mellitus; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BFP: Body fat percentage; WHR: Waist-Hip ratio; AC: Upper arm circumference

AMC: Upper arm muscle circumference; BMR: Basal metabolic rate; PhA: Phase angle; LBM: Lean body mass; VFA: Visceral fat area; IS: Inorganic salts; BMC: Bone mineral content; SMM: Skeletal muscle mass; ECW: Extracellular water; ICW: Intracellular water; OH: Extra water; E/T: Extracellular water ratio; Hb: Hemoglobin; Glu: Blood glucose; Hs-CRP: Hypersensitive C-reactive protein; Ca²⁺: Serum calcium; P⁺: Serum phosphorus; K⁺: Serum potassium; Na⁺: Serum sodium; Cl⁻: Serum chloride; ALB: Serum albumin; TIBC: Total iron-binding force; FER: Ferroprotein; SI: Serum iron; TS: Transferrin saturation; Cr: Serum creatinine; UA: serum uric acid; BUN: Serum urea; HCO₃⁻: Bicarbonate; PA: Prealbumin; TG: Triglycerides; TC: Total cholesterol; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; VLDL: Very low-density lipoprotein; ALP: Alkaline phosphatase; PTH: Parathyroid hormone.

3. The relationship between PhA and diagnostic indicators of sarcopenia.

Pearson correlation analysis shows a positive correlation between PhA with HGS, skeletal muscle mass (SMM), and ACM, but not with ASMI and muscle mass (Model 1). After adjustments for age, diabetes, BMI, E/T, OH, serum creatinine level, total Kt/V, and residual Kt/V, the positive correlation between PhA with HGS and muscle circumference of upper arm remained (Model 7), except for SMM, ASMI, and muscle mass (Table 2).

Table 2 The person correlation between PhA with Indicators related to sarcopenia

Model variables	Model 1		Model 2		Model 3		Model 4		Model 5		Model 6		Model 7	
	r	p	r	p	r	p	r	p	r	p	r	p	r	p
PhA×HGS	0.49	<0.01	0.22	0.04	0.21	0.06	0.19	0.08	0.17	0.14	0.26	0.02	0.23	0.048
PhA×ASMI	0.18	0.09	-0.07	0.52	-0.23	0.04	-0.22	0.05	-0.14	0.20	-0.14	0.32	-0.11	0.34
PhA×muscle mass	0.19	0.08	-0.16	0.15	0.27	0.01	0.20	0.08	0.2	0.08	0.19	0.1	0.10	0.37
PhA×SMM	0.26	0.02	-0.05	0.65	0.27	0.01	0.20	0.08	0.2	0.08	0.19	0.1	0.10	0.37
PhA×AMC	0.42	<0.01	0.51	<0.01	0.30	<0.01	0.28	0.01	0.31	<0.01	0.31	<0.01	0.24	0.03

Model 1 Univariate correlation; Model 2 adjusted for sex, age, diabetes, and BMI; Model 3 adjusted for sex, age, diabetes, BMI, and Extracellular water ratio; Model 4: adjusted for sex, age, diabetes, BMI, Extracellular water ratio and extra water; Model5: adjusted for sex, age, diabetes, BMI, Extracellular water ratio, extra water, and serum creatinine; Model 6: adjusted for sex, age, diabetes, BMI, Extracellular water ratio, extra water, serum creatinine, and total kt/v; Model 7: adjusted for sex, age, diabetes, BMI, Extracellular water ratio, extra water, serum creatinine, total kt/v, and residual kt/v.

4. Univariate and Multivariate logistic regression between PhA and sarcopenia.

A univariate logistic regression between PhA and sarcopenia (Table 3) shows that with PhA Q1 as the baseline level, the ORs for the risk of disease for Q2, Q3, and Q4 is 0.583(95%CI 3.15-248.78), 0.163(95%CI 1.75-152.82) and 0.036(95%CI 0.492-42.33). The Q1, Q2, Q3, and Q4 are the quartile levels of the PhA. The risk of sarcopenia decreases with increasing PhA. However, after adjustments for age, total Kt/V, residual kidney Kt/V, basal metabolic, OH, E/T, and serum creatinine, PhA is

not a risk factor for sarcopenia($P>0.05$). As the diagnostic criteria included HGS and ASMI, HGS and muscle-related indicators such as SMM and muscle mass were excluded from the logistic regression.

Table 3 Logistic Regression analysis for sarcopenia according to different variables.

Model	univariate		multivariate	
Variables	Odds ration(95%CI)	p	Odds ration(95%CI)	p
Phase angle		0.003		0.710
Q2(ref Q1)	0.583(3.151-248.774)	0.003	3.076(0.025-372.251)	0.646
Q3(ref Q1)	0.163(1.746-152.822)	0.014	0.348(0.004-0.65)	0.650
Q4(ref Q1)	0.036(0.492-42.33)	0.181	0.123(0-68.623)	0.516
Age		<0.01		0.069
Age \geq 45 (ref age<45)	4.762(0.494-45.945)	0.177	30.437(0.534-1707.367)	0.096
Age \geq 55	14.286(1.616-126.297)	0.017	47.507(0.613-3683.278)	0.082
Age \geq 65	150(12.347-1822.25)	<0.01	675.960(4.919-92894.294)	0.009
E/T(ref E/T\leq0.4)	3.479(1.287-9.408)	0.014	1.127(0.015-86.132)	0.957
OH		0.014		0.459
Q2(ref Q1)	1.895(0.308-11.644)	0.490	0.253(0.006-10.882)	0.474
Q3	10.800(2.003-58.224)	<0.01	3.294(0.042-257.569)	0.592
Q4	4.2(0.756-23.232)	0.101	1.266(0.003-525.443)	0.939
Basal metabolic ration		0.1		0.342
Q2(ref Q1)	2.083(0.588-7.383)	0.256	19.486(0.701-541.805)	0.080
Q3	1.167(0.317-4.299)	0.817	4.059(0.181-91.23)	0.378
Q4	0.25(0.044-1.417)	0.117	3.547(0.038-331.756)	0.585
Total Kt/V		0.023		0.115
Total kt/v \geq 1.544 (ref total kt/v<1.544)	1.333(0.26-6.828)	0.73	4.705(0.081-272.491)	0.455
Total kt/v \geq 1.797 (ref total kt/v<1.544)	2.25(0.482-10.504)	0.302	10.714(0.169-677.935)	0.262
Total kt/v \geq 2.013 (ref total kt/v<1.544)	7.2(1.635-31.712)	<0.01	121.131(1.660-8839.286)	0.028
Residual kidney Kt/V(ref 无)	3.806(1.386-10.447)	<0.01	1.77(0.224-13.971)	0.588
Serum creatinine		<0.01		0.530
Q2(ref Q1)	0.287(0.082-1.01)	0.052	0.927(0.057-15.11)	0.958
Q3	0.137(0.034-0.552)	<0.01	2.809(0.121-65.12)	0.520
Q4	0.029(0.003-0.262)	<0.01	0.119(0.002-6.084)	0.289

The Q1, Q2, Q3, and Q4 are the quartile levels of each variable

5. AUROC of PhA for sarcopenia

The AUROC of PhA for sarcopenia is 0.76(95% CI, 0.65-0.86, $P<0.01$, fig 3).

The optimal cut-off value is ≤ 5.25 (sensitivity 74%, specificity 76%,fig3). On the

other hand, the AUROC of males is 0.85(95%CI, 0.73-0.97), and the cut-off point of PhA for males is 5.25(sensitivity 81.8%, specificity 80%,fig 1). Whereas the AUROC of females is 0.67, and the best predictive value of PhA for sarcopenia is 5.1 (sensitivity 69%, specificity 73%,fig 2), which is lower than for men.

Discussion

Primary sarcopenia is an age-related syndrome characterized by reduced SMM, muscle strength, and muscle function[14], which is associated with various negative outcomes such as falls, disabilities, fractures, and death. Some studies[15, 16] illustrated that the worsened kidney function is associated with an increased prevalence of sarcopenia, especially in dialysis patients. Thus, early diagnosis and intervention of sarcopenia are important for dialysis patients.

The BIA has been used for the last decades for body composition analysis since its simplicity and less harm to the human body[17]. PhA, one of the parameters of BIA, reflects the number of cells and cells' integrity and has been shown to correlate with nutritional status and sarcopenia. In 2012[18], Marini et al. enrolled 207 elderly and compared the PhA between non-sarcopenia and sarcopenia groups identified by Dual-energy X-ray absorptiometry (DXA). They found PhA was lower in the sarcopenia group and positively correlated with skeletal muscle mass index (SMI). Our study also finds that compared with the non-sarcopenia group, sarcopenia patients have a lower PhA. Meanwhile, in univariate analysis, PhA positively correlated to HGS, SMM, and AMC. But after adjustments for sex, age, diabetes, BMI, Extracellular water ratio, extra water, serum creatinine, total kt/v, and residual kt/v,

only HGS and AMC remain associated with PhA. In the multivariate logistic regression analysis, we find no correlation between PhA and sarcopenia. The result is different from the many previous findings. In the elder, Elisabetta Marini et al. found PhA was positively associated with SMI both in male and female (men: $r = 0.52$, $p < 0.01$; women: $r = 0.31$, $p < 0.01$) [18]. Another study [19] demonstrated a moderate correlation between PhA with HGS. Akihiro et al. revealed that PhA negatively correlated to sarcopenia after a multivariate logistic regression in kidney transplant patients. Han B et al [20] enrolled 80 patients undergoing PD showed that PhA correlated to serum albumin and lean tissue index (LTI) from bioimpedance. Recently, research including 200 patients with PD [21] demonstrated that PhA is independently associated with muscle mass, strength, and sarcopenia, but they used DXA to measure body composition. Whereas, in 2020, Pessoa et al. illustrated that PhA had no association with sarcopenia, SMI, HGS, and walk speed in the old women [22]. Another study in kidney transplant patients [23] also thought PhA was not associated with sarcopenia but with HGS. BIA, consistent with our findings, measured the body composition. Thus, different methods to measure body composition may cause different results between PhA and body composition. Whether PhA is related to sarcopenia and body composition needs more large sample studies.

Upper arm circumference and AMC are both reliable indicators of nutritional status. Still, patients undergoing PD are prone to fat accumulation due to glucose in the peritoneal fluid. Upper arm muscle circumference is a better indicator of

nutritional status. An observational cross-sectional study found that mid-arm circumference could act as a predictor of sarcopenia[24]. There are no studies on the relationship between AMC and sarcopenia. To our knowledge, this is the first study to find that PhA correlated to the AMC. However, our method of measuring AMC is BIA rather than the traditional measurement of upper arm circumference and skinfold thickness. The correlation between AMC and PhA needs more research.

We also find that age \geq 65 is an independent risk factor for sarcopenia, which is consistent with the previous study. Except for age, male gender[16], lower BMI[16, 23], diabetes, longer dialysis duration[24], malnutrition(such as lower serum albumin/pre-albumin)[7, 25], and high-sensitive C-reactive protein(Hs-CRP)[26, 27] were found associated with sarcopenia also in a multivariate logistic regression. Our study also finds serum albumin and pre-albumin are lower in sarcopenia than the non-sarcopenia group, but not sex, BMI, dialysis duration, diabetes, and Hs-CRP. The multivariate regression analysis shows that they are not associated with sarcopenia. This may be caused by the small sample size of our study and the different diagnostic criteria. Meanwhile, after adjustments for other components, the prevalence of sarcopenia is seven times higher in patients with total Kt/V $>$ 2.013 than in those with total Kt/V $<$ 1.544(OR=7.2, 95% CI:1.635-31.712, P $<$ 0.01). A higher Kt/V indicates that the patient is adequately dialyzed, but the dialysis dose is too high. Nutrients such as protein can be lost from the peritoneal fluid, the most important nutrient in muscle synthesis. This may account for the higher risk of sarcopenia in patients with higher Kt/V. This is the first study that demonstrates total Kt/V is a risk factor for

sarcopenia, but it is a single-center study, and the result needs to be confirmed by more studies.

In the univariate logistic regression model, PhA correlated to sarcopenia. Thus, we still use ROC curve analysis to find the cut-off value for sarcopenia by phase angle in patients with peritoneal dialysis fluid. We find the best cut-off value of PhA is 5.25° . For males, the best value is $\text{PhA} \leq 5.25^\circ$ and the best value is $\text{PhA} \leq 5.1^\circ$ for females, which is lower than males. Yamada et al. illustrated that the average PhA for sarcopenia is 4.05° for men and 3.55° for women in community-dwelling Japanese old people[19]. A study[28] on elderly inpatients showed the optimal PhA cut-off value was $\leq 4.55^\circ$ (sensitivity 70% and specificity 65.9%). In 2019[29], a value $\leq 5.05^\circ$ was indicated in cirrhosis (sensitivity 71.3% and specificity is 65.5%). Kosoku et al. demonstrated a value of ≤ 4.46 in kidney transplant patients, with a sensitivity of 74% and specificity of 70%[30]. Recently, a study about peritoneal dialysis without peritoneal dialysis fluid showed the cut-off value was $\leq 4.4^\circ$ (sensitivity 81.3%, specificity 59.6%)[21]. This may be since the total average age of our central dialysis patients (51.3 ± 12.43 year) are lower than that of the patients included in the study (55.5 ± 12.2 year). Except for this, race can also influence PhA. Our study shows a higher cut-off value for males than females, which is consistent with previous studies due to higher muscle mass and lower fat mass in males compared with females. However, whether it can be used as a diagnostic indicator of sarcopenia is related to gender, and its diagnostic significance for male sarcopenia may be greater.

The advantages of our study are the following: 1. Several previous studies on sarcopenia had used incomplete criteria, but they used muscle mass alone. Our study uses two variables (HGS and SMI) to diagnose sarcopenia. 2. We use consensus and definitions of sarcopenia for Asia populations.

Our study also has some limitations: 1. This study is a Single-Centre study with a small sample size, and our results still need to be confirmed by large sample, multicenter trials. 2. For the body composition analysis, BIA is used instead of DXA. A guideline suggests that performing would be more reasonable than using a BIA to measure muscle mass in peritoneal dialysis patients.

In conclusion, we find older age and higher total kt/v are risk factors for sarcopenia. PhA is positively associated with HGS and AMC but not with sarcopenia in CAPD patients. These results suggest that PhA can be used as a predictor of muscle mass and strength in CAPD patients, but its' diagnosis value for sarcopenia needs more studies.

Acknowledgments: Not applicable.

References:

1. Nascimento CM, Ingles M, Salvador-Pascual A, Cominetti MR, Gomez-Cabrera MC, Viña J: **Sarcopenia, frailty and their prevention by exercise**. *FREE RADICAL BIO MED* 2019, **132**:42-49.
2. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA *et al*: **Sarcopenia: revised European consensus on definition and diagnosis**. *AGE AGEING* 2019, **48**(1):16-31.
3. Kiebalo T, Holotka J, Habura I, Pawlaczyk K: **Nutritional Status in Peritoneal Dialysis: Nutritional Guidelines, Adequacy and the Management of Malnutrition**. *NUTRIENTS* 2020, **12**(6):1715.
4. Abro A, Delicata L, Vongsanim S, Davenport A: **Differences in the prevalence of sarcopenia in peritoneal dialysis patients using hand grip strength and appendicular lean mass: depends upon guideline definitions**. *EUR J CLIN NUTR* 2018, **72**(7):993-999.
5. Da Silva MZC, Vogt BP, Reis NSDC, Caramori JCT: **Update of the European consensus on**

sarcopenia: what has changed in diagnosis and prevalence in peritoneal dialysis? *EUR J CLIN NUTR* 2019, **73**(8):1209-1211.

6. Hotta C, Hiraki K, Wakamiya A, Otobe Y, Watanabe S, Izawa KP, Kaneshiro N, Konno Y, Sakurada T, Shibagaki Y *et al*: **Relation of physical function and physical activity to sarcopenia in hemodialysis patients: A preliminary study.** *INT J CARDIOL* 2015, **191**:198-200.

7. Kamijo Y, Kanda E, Ishibashi Y, Yoshida M: **Sarcopenia and Frailty in PD: Impact on Mortality, Malnutrition, and Inflammation.** *Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis* 2018, **38**(6):447-454.

8. Kim J, Kim SG, Oh J, Lee Y, Noh J, Kim HJ, Song YR: **Impact of sarcopenia on long-term mortality and cardiovascular events in patients undergoing hemodialysis.** *The Korean Journal of Internal Medicine* 2019, **34**(3):599-607.

9. Di Vincenzo O, Marra M, Di Gregorio A, Pasanisi F, Scalfi L: **Bioelectrical impedance analysis (BIA) -derived phase angle in sarcopenia: A systematic review.** *CLIN NUTR* 2021, **40**(5):3052-3061.

10. Sabatino A, Cuppari L, Stenvinkel P, Lindholm B, Avesani CM: **Sarcopenia in chronic kidney disease: what have we learned so far?** *J NEPHROL* 2020, **34**(prepublish).

11. de França NAG, Callegari A, Gondo FF, Corrente JE, Mclellan KCP, Burini RC, de Oliveira EP: **Higher dietary quality and muscle mass decrease the odds of low phase angle in bioelectrical impedance analysis in Brazilian individuals.** *NUTR DIET* 2016, **73**(5):474-481.

12. Basile C, Della-Morte D, Cacciatore F, Gargiulo G, Galizia G, Roselli M, Curcio F, Bonaduce D, Abete P: **Phase angle as bioelectrical marker to identify elderly patients at risk of sarcopenia.** *EXP GERONTOL* 2014, **58**:43-46.

13. Yamada M, Kimura Y, Ishiyama D, Nishio N, Otobe Y, Tanaka T, Ohji S, Koyama S, Sato A, Suzuki M *et al*: **Phase Angle is a Useful indicator for Muscle Function in Older Adults.** *The journal of nutrition, health & aging* 2019, **23**(3):251-255.

14. Nascimento CM, Ingles M, Salvador-Pascual A, Cominetti MR, Gomez-Cabrera MC, Viña J: **Sarcopenia, frailty and their prevention by exercise.** *FREE RADICAL BIO MED* 2019, **132**:42-49.

15. Vettoretti S, Caldiroli L, Armelloni S, Ferrari C, Cesari M, Messa P: **Sarcopenia is Associated with Malnutrition but Not with Systemic Inflammation in Older Persons with Advanced CKD.** *NUTRIENTS* 2019, **11**(6):1378.

16. Ishikawa S, Naito S, Iimori S, Takahashi D, Zeniya M, Sato H, Nomura N, Sohara E, Okado T, Uchida S *et al*: **Loop diuretics are associated with greater risk of sarcopenia in patients with non-dialysis-dependent chronic kidney disease.** *PLOS ONE* 2018, **13**(2):e192990.

17. Silva VM, Silva MZC, Vogt BP, Reis NSC, Costa FL, Dorna MS, Minicucci MF, Caramori JCT: **Association of Phase Angle, but Not Inflammation and Overhydration, With Physical Function in Peritoneal Dialysis Patients.** *Frontiers in Nutrition* 2021, **8**.

18. Marini E, Buffa R, Saragat B, Coin A, Toffanello ED, Berton L, Manzato E, Sergi G: **The potential of classic and specific bioelectrical impedance vector analysis for the assessment of sarcopenia and sarcopenic obesity.** *CLIN INTERV AGING* 2012, **7**:585-591.

19. Yamada M, Kimura Y, Ishiyama D, Nishio N, Otobe Y, Tanaka T, Ohji S, Koyama S, Sato A, Suzuki M *et al*: **Phase Angle is a Useful indicator for Muscle Function in Older Adults.** *The journal of nutrition, health & aging* 2019, **23**(3):251-255.

20. Han B, Lee J, Kim J, Yang J: **Clinical Significance of Phase Angle in Non-Dialysis CKD Stage 5 and Peritoneal Dialysis Patients.** *NUTRIENTS* 2018, **10**(9):1331.

21. Do JY, Kim AY, Kang SH: **Association Between Phase Angle and Sarcopenia in Patients**

Undergoing Peritoneal Dialysis. *Frontiers in Nutrition* 2021, **8**.

22. Pessoa DF, de Branco FMS, Dos Reis AS, Limirio LS, Borges LDP, Barbosa CD, Kanitz AC, de Oliveira EP: **Association of phase angle with sarcopenia and its components in physically active older women.** *AGING CLIN EXP RES* 2020, **32**(8):1469-1475.
23. Dos Reis AS, Santos HO, Limirio LS, de Oliveira EP: **Phase Angle Is Associated With Handgrip Strength but Not With Sarcopenia in Kidney Transplantation Patients.** *J RENAL NUTR* 2019, **29**(3):196-204.
24. Bataille S, Serveaux M, Carreno E, Pedinielli N, Darmon P, Robert A: **The diagnosis of sarcopenia is mainly driven by muscle mass in hemodialysis patients.** *CLIN NUTR* 2017, **36**(6):1654-1660.
25. Isoyama N, Qureshi AR, Avesani CM, Lindholm B, Båràny P, Heimbürger O, Cederholm T, Stenvinkel P, Carrero JJ: **Comparative Associations of Muscle Mass and Muscle Strength with Mortality in Dialysis Patients.** *CLIN J AM SOC NEPHRO* 2014, **9**(10):1720-1728.
26. Souza VAD, Oliveira D, Barbosa SR, Corrêa JODA, Colugnati FAB, Mansur HN, Fernandes NMDS, Bastos MG: **Sarcopenia in patients with chronic kidney disease not yet on dialysis: Analysis of the prevalence and associated factors.** *PLOS ONE* 2017, **12**(4):e176230.
27. Tabibi H, As'Habi A, Najafi I, Hedayati M: **Prevalence of dynapenic obesity and sarcopenic obesity and their associations with cardiovascular disease risk factors in peritoneal dialysis patients.** *Kidney Research and Clinical Practice* 2018, **37**(4):404-413.
28. Kilic MK, Kizilarlanoglu MC, Arik G, Bolayir B, Kara O, Dogan Varan H, Sumer F, Kuyumcu ME, Halil M, Ulger Z: **Association of Bioelectrical Impedance Analysis – Derived Phase Angle and Sarcopenia in Older Adults.** *NUTR CLIN PRACT* 2017, **32**(1):103-109.
29. Espirito Santo Silva DD, Waitzberg DL, Passos De Jesus R, Oliveira LPMD, Torrinhas RS, Belarmino G: **Phase angle as a marker for sarcopenia in cirrhosis.** *Clinical Nutrition ESPEN* 2019, **32**:56-60.
30. Kosoku A, Uchida J, Nishide S, Kabei K, Shimada H, Iwai T, Maeda K, Hanayama Y, Ishihara T, Naganuma T *et al*: **Association of sarcopenia with phase angle and body mass index in kidney transplant recipients.** *SCI REP-UK* 2020, **10**(1).

Declarations.


Ethics approval and consent to participate: The Ethics Committee approved the study protocol of The Third Hospital of Hebei Medical University (number:20210931). All subjects signed an informed consent form.

Consent for publication: Not applicable.


Availability of data and materials Not applicable.

Competing interests The authors declare that they have no conflict of interest.


Funding This study was funded by The government subsidizing the training program for outstanding clinical medical talents in 2021, study on nutrition evaluation and intervention of chronic kidney disease population- based on machine learning(103), Hebei Provincial Health Commission. It Provides funding for following up patients and finding papers .



Figure



Figure



Figure

Fig 1 The ROC curve of PhA for sarcopenia in males, the AUCROC is 0.85($p < 0.01$).

Fig 1 The ROC curve of PhA for sarcopenia in females, the AUCROC is 0.67($p = 0.07$).

Fig 3 The ROC curve of PhA for sarcopenia in all of the patients, the AUCROC is 0.76($p < 0.01$).

medRxiv preprint doi: <https://doi.org/10.1101/2022.07.10.22277470>; this version posted July 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).